Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORY-3
NCT06884293Phase 3Active, not recruiting
- Sponsor
- Innovent Biologics
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in metabolic dysfunction associated fatty liver disease (MAFLD), sponsored by Innovent Biologics. Started May 2025; status: active, not recruiting.
02
Drugs
mazdutide
03
Conditions
metabolic dysfunction associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT06884293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884293.